# Nuclein, LLC: Form D capital raise (Austin, TX)

**Vendor Spend Propensity Score (CPA / Tax / Audit):** 63/100
**Estimated post-raise budget for this service type:** $313,010 (heuristic)

| Field | Value |
|---|---|
| Industry | Biotechnology (Healthcare & Life Sciences) |
| Operating company | Yes |
| Exemption | 506(b) |
| Amount sold | $15,650,488 |
| Total offering | $26,114,842 |
| Investors so far | 25 |
| First sale | 2026-06-04 |
| Filed | 2026-10-27 (amendment) |
| Entity | Limited Liability Company |

## Executives and related persons (as listed in the filing)
- Alan Blake: Executive Officer, Director
- Richard Crockett: Director
- William Cunningham: Director
- Douglas Bryant: Director
- Sanjay Chandra: Director
- H. David Shockley: Director
- Walter Narajowski: Director
- Jeffrey Stukuls: Executive Officer

## Why this score
- Operating company: new capital typically funds hiring, facilities and vendors.
- Raised $15,650,488 so far.
- Healthcare & Life Sciences companies are a strong fit for CPA / Tax / Audit services.

Source: SEC EDGAR Form D filings (U.S. Securities and Exchange Commission) (https://www.sec.gov/Archives/edgar/data/1787352/000178735226000005/). Last refreshed: 2026-11-04T01:28:40.459Z.
Informational only. SEC EDGAR Form D data is shown for business-development research; it is not investment advice and not an offer or solicitation to buy or sell any security. Not legal or financial advice.